Royalty Report: Drugs, Cancer, Disease – Collection: 282871

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282871

License Grant
Licensee and the Canadian Licensor amend certain provisions of the Agreement granted to include but not limited to milestone and royalty payments with respect to a Product being commercialized.
License Property
Product means any member of the class of substituted 4-H chromenes, analogs and derivatives thereof and any compound encompassed by the generic chemical formulae.
Field of Use
MX2105 series of vascular targeting agent cancer drug candidates.

IPSCIO Record ID: 240463

License Grant
Licensor hereby grants to Canadian Licensee an exclusive, worldwide, royalty-bearing license, including the right to grant sublicenses (which themselves may include the right to grant further sublicenses), under the Licensor Patent Rights and Licensor Know-How to research, develop, make and have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Products in the Field.
License Property
Product means any member of the class of substituted 4-H chromenes, analogs and derivatives including all formulations and modes of administration thereof.  In addition, the Product as defined above shall also mean any further member of the broader class of substituted 4-H chromenes, analogs and derivatives as described in any claim of U.S. application no. 60/185,211 as filed that shall be included in the Research Program pursuant to this Agreement.
Field of Use
Licensing agreement is for a series of anticancer compounds (CV2105).  CV2105 stimulates specific activity in caspases, enzymes that modulate and carry out the cellular signaling pathways involved in apoptosis.  CV2105 compounds have shown the potential to be effective where current chemotherapeutic compounds have not worked due to drug resistance. We believe that CV2105 may prove to provide a benefit to patients for whom their cancer therapy is currently impaired by such drug resistance.'

IPSCIO Record ID: 240572

License Grant
The Canadian Licensor hereby grants to Licensee an exclusive, worldwide, royalty-bearing license, including the right to grant sublicenses (which themselves may include the right to grant further sublicenses), under the Licensor Patent Rights, the Licensor Know-How and Licensor’s interest in the Joint Patents, to research, develop, make and have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Products in the Field.
License Property
Joint Patent Rights as they exist as of the Effective Date are set forth hereto.

Application Patents
10/146,138 – SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
10/146,136 – Substituted  COUMARINS AND QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF

Field of Use
Patent relate to the MX2105 series of vascular targeting agent cancer drug candidates.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.